US-based Merck & Co (NYSE: MRK) has won priority review in the USA for a new supplemental Biologics License Application (sBLA) for Keytruda (pembrolizumab).
The decision means the firm’s application to market the drug for certain Merkel cell carcinoma (MCC) patients will be given special attention by the US regulator. MCC is a rare and aggressive form of skin cancer.
Currently, German rival Merck KGaA (MRK: DE) and New York’s Pfizer (NYSE: PFE) are the only firms with an approved medication in this class to treat the indication, with Bavencio (avelumab).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze